These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16932638)

  • 1. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.
    Humbert M; Simonneau G
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
    Steiner MK; Preston IR
    Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of pulmonary arterial hypertension: role of ambrisentan.
    Barst RJ
    Vasc Health Risk Manag; 2007; 3(1):11-22. PubMed ID: 17583171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
    Waxman AB
    Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N; Derk CT
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
    McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ
    Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.
    Luo N; Ryan JJ
    Can J Cardiol; 2013 Jun; 29(6):659-61. PubMed ID: 22985784
    [No Abstract]   [Full Text] [Related]  

  • 11. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Langleben D
    Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
    Rubin LJ
    Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitaxsentan sodium for pulmonary hypertension.
    MacIntyre IM; Dhaun N; Goddard J; Webb DJ
    Drugs Today (Barc); 2008 Aug; 44(8):585-600. PubMed ID: 18846270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
    Gabler NB; French B; Strom BL; Liu Z; Palevsky HI; Taichman DB; Kawut SM; Halpern SD
    Chest; 2012 Jan; 141(1):20-26. PubMed ID: 21940766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
    Price LC; Howard LS
    Am J Cardiovasc Drugs; 2008; 8(3):171-85. PubMed ID: 18533738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade.
    Zacà V; Metra M; Danesi R; Lombardi C; Verzura G; Dei Cas L
    Ther Adv Respir Dis; 2009 Feb; 3(1):11-4. PubMed ID: 19293198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].
    Batyraliev TA; Makhmutkhodzhaev SA; Ekinsi E; Pataraia SA; Pershukov IV; Sidorenko BA; Preobrazhenskiĭ DV
    Kardiologiia; 2007; 47(7):73-82. PubMed ID: 18260899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.